CORCEPT THERAPEUTICS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Maduck Sean (See Remarks) sold 30,955 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $125.58 ($125.47–$126.06, $3.89M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
MAHONEY DAVID L sold 103,606 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $118.25 ($117.47–$119.64, $12.25M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning CORT (CORCEPT THERAPEUTICS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CORT coverage spans insider activity, market movers and earnings.
In the last 30 days, CORT insiders filed 30 SEC Form 4 transactions — no purchases and 30 sales ($32.9M). The most active reporter was Mokari Atabak, Chief Financial Officer, with 13 filings. 93% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale by an officer may signal reduced confidence, but size is modest.
Revenue beat and product momentum support bullish sentiment.
Significant insider sell by a director may signal negative sentiment.
A director’s indirect open-market sale under a 10b5-1 plan is typically not a fundamental signal, but it can affect near-term sentiment and positioning.
The filing is a routine insider sale with no 10b5-1 plan stated, which can modestly affect near-term sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions CORT with an AI model for sentiment and relevance, and aggregates insider trades from CORCEPT THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Maduck Sean (See Remarks) sold 30,955 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $125.58 ($125.47–$126.06, $3.89M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readSeveral biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readMAHONEY DAVID L sold 103,606 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $118.25 ($117.47–$119.64, $12.25M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readWILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $111.43 ($110.49–$112.64, $1.11M total) across 3 trades on 2026-08-14 under a Rule 10b5-1 trading plan.
1 min readRobb Gary Charles (Chief Business Officer) sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $116.26 ($1.16M total) on 2026-08-17.
1 min readGuyer William (Chief Development Officer) sold 16,300 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.43 ($113.18–$114.04, $1.85M total) across 2 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min readCorcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.
3 min readMaduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readLyon Joseph Douglas (See Remarks) sold 1,540 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.16 ($0.18M total) on 2026-08-03.
1 min readMokari Atabak (Chief Financial Officer) sold 80,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.71 ($105.54–$120.67, $9.18M total) across 13 trades on 2026-07-30 under a Rule 10b5-1 trading plan.
2 min read